These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8097002)

  • 1. Flosequinan and arrhythmogenesis.
    Noble J; Farrer M; McComb JM
    Lancet; 1993 Apr; 341(8852):1100. PubMed ID: 8097002
    [No Abstract]   [Full Text] [Related]  

  • 2. Flosequinan withdrawn.
    Lancet; 1993 Jul; 342(8865):235. PubMed ID: 8100947
    [No Abstract]   [Full Text] [Related]  

  • 3. Ventricular arrhythmias associated with flosequinan.
    Carson JJ; Lober CA; Turi AR
    Ann Pharmacother; 1994 Mar; 28(3):403-4. PubMed ID: 8193436
    [No Abstract]   [Full Text] [Related]  

  • 4. Flosequinan and renovascular disease.
    Wood SM; Dudley CR; Devaney AM; Winearls CG
    Lancet; 1993 Jan; 341(8837):116-7. PubMed ID: 8093384
    [No Abstract]   [Full Text] [Related]  

  • 5. The flosequinan experience and its implications.
    Fath-Ordoubadi F
    Br J Hosp Med; 1993 Dec 15-1994 Jan 18; 50(11):683; author reply 683-4. PubMed ID: 8124555
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of flosequinan and nifedipine on glucose tolerance in healthy volunteers.
    Lewis H; Kendall M; Bratty JR
    J Clin Pharm Ther; 1988 Aug; 13(4):269-72. PubMed ID: 3235476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible role of metabolite in flosequinan-related mortality.
    Kamali F; Edwards C
    Clin Pharmacokinet; 1995 Dec; 29(6):396-403. PubMed ID: 8787946
    [No Abstract]   [Full Text] [Related]  

  • 8. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
    Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
    Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flosequinan for chronic heart failure?
    Drug Ther Bull; 1993 Jun; 31(12):47-8. PubMed ID: 8344139
    [No Abstract]   [Full Text] [Related]  

  • 10. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
    Schneeweiss A; Marmor A; Wynne RD
    Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of OPC-8212, an inotropic agent, in patients with chronic congestive heart failure--a multiple dose evaluation on its effect and arrhythmogenesis].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Oct; 36(10):1125-31. PubMed ID: 3247528
    [No Abstract]   [Full Text] [Related]  

  • 12. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure.
    Silke B; Tennet H; Fischer-Hansen J; Keller N; Heikkila J; Salminen K
    Eur Heart J; 1992 Aug; 13(8):1092-100. PubMed ID: 1505560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of concurrent administration of flosequinan and digoxin on the pharmacokinetics of each drug.
    Rau R; Hind ID; Wynne RD; White SA
    Arzneimittelforschung; 1994 Mar; 44(3):300-4. PubMed ID: 8192694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the effects of flosequinan, a new vasodilator, and propranolol on sub-maximal exercise in healthy volunteers.
    Lewis HM; Kendall MJ; Smith SR; Bratty JR
    Br J Clin Pharmacol; 1989 May; 27(5):547-52. PubMed ID: 2757879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
    Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
    Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.
    Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF
    Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dysrhythmias linked with phenoxedil (author's transl)].
    Puech P; Bosc E; Grolleau R; Cabasson J; Mellet JM; Ferrières M
    Ann Cardiol Angeiol (Paris); 1976; 25(4):297-302. PubMed ID: 949169
    [No Abstract]   [Full Text] [Related]  

  • 18. [Letter: Possible responsibility of a peripheral vasodilator agent, fenoxedil, in the occurrence of heart rhythm disorders].
    Barraine R; Ariès J; Druart F; Casteigt JM; Benabbou M; Valois M; Marin J; Demange J; Rousseau G
    Nouv Presse Med; 1975 Dec; 4(42):3008-9. PubMed ID: 1221355
    [No Abstract]   [Full Text] [Related]  

  • 19. The effects of flosequinan on regional blood flow in normal man.
    Scott RA; Woods KL; Barnett DB
    Br J Clin Pharmacol; 1991 Jan; 31(1):41-6. PubMed ID: 2015169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letter: Spike torsade. Possibly caused by a peripheral vasodilator: fenoxedil].
    Guillou M; Cariou A; Blanc JJ; Boschat J; Granatelli D; Penther P
    Nouv Presse Med; 1975 Sep; 4(29):2118 (1). PubMed ID: 1178475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.